Import alerts and detention without physical examination: what a border refusal establishes, and what it does not

Regulatory events attach themselves to suppliers, and the surrounding commentary tends to read them as verdicts. A firm appears on an FDA import alert and the event is reported in one of two registers: as proof that the material was tested and found defective, or as a bureaucratic inconvenience with no bearing on quality at all. Both readings assume that a border action is an assessment of the article’s composition. It is not. The mechanism has a specific legal standard, a specific evidentiary posture, and a name that states plainly what it does not involve — detention without physical examination. This post sets out how that mechanism works, what an import alert listing represents, how a listing is removed, and where the analytical record sits relative to all of it.

The standard is appearance, not finding

Chapter VIII of the Federal Food, Drug, and Cosmetic Act governs imports. Section 801(a) sets the threshold for refusing an article admission into the United States, and the operative language is about what appears to be the case — from examination of samples, or otherwise. That last clause does most of the work. An article can be refused on information that is not a laboratory result on the shipment in front of the inspector: the manufacturer’s inspection history, the declared identity of the product, labelling, the regulatory status of the substance, prior entries from the same firm.

This is a deliberately low bar, and it is low for a structural reason. An import decision is not an adjudication: FDA is not determining that an article violates the Act, but whether it may enter. The burden of demonstrating admissibility sits with the owner or consignee, and the procedural rules in 21 CFR Part 1, Subpart E reflect that allocation — when it appears an article may be refused, the division director issues notice stating the reasons, and specifies a place and a period during which the owner or consignee may introduce testimony confined to matters relevant to admissibility. The opportunity is real, but it is an opportunity to rebut an appearance, not to contest a finding, because no finding has been made.

The practical consequence is immediate. A refusal tells you that a shipment failed to clear a threshold defined in terms of appearance. It does not tell you that anything in the shipment was measured.

Detention without physical examination

Detention without physical examination — DWPE in the agency’s shorthand — is the operational instrument built on that standard. Rather than reviewing each entry individually, FDA maintains import alerts: standing instructions to field divisions that entries matching a described pattern may be detained on arrival without sampling or testing. The pattern may be defined by product, by firm, by country, or by some combination, and the firms and products subject to it are enumerated on what the agency calls the red list.

The general considerations governing when a product, firm, or country may be subjected to DWPE, and the considerations for removal, are set out in Chapter 9 of FDA’s Regulatory Procedures Manual. The design is triage. Physical examination is expensive and slow, entry volumes are enormous, and a standing alert lets the agency concentrate examination resources where historical information suggests a violation is more likely. Once an alert is in force, the default flips: entries that would otherwise pass are held, and the importer supplies the evidence that the shipment is admissible.

The name is the substance of the thing. A detention under an import alert is, by construction, not the result of testing the detained material.

Import Alert 66-41 and the regulatory-status basis

The alert most often relevant to bulk synthetic peptides is Import Alert 66-41, covering detention without physical examination of unapproved new drugs promoted in the United States. Its stated rationale is that such drugs have not been reviewed by FDA for safety or effectiveness, so there is no basis for knowing whether they are safe and effective for their intended use, whether they are manufactured under conditions producing consistent quality, or whether their labelling is complete and accurate. Field divisions may detain the identified products from firms on the alert’s red list. The alert notes that commercial or promotional shipments subject to DWPE are generally not amenable to enforcement discretion, and that securing release of an individual shipment requires the owner, consignee, or another responsible party to provide evidence that the shipment does not contain unapproved new drug products. It was most recently revised on 19 May 2026.

The logic of 66-41 is worth stating precisely, because it is the source of most misreading. The violation the alert addresses is a status — the article is an unapproved new drug — and status attaches to the substance together with how it is represented, not to the purity of the powder. Promotion is the hinge. An article promoted for a use that makes it a drug, without an approved application covering it, is in violation regardless of how well it was synthesised, and a material of exceptional analytical quality is exactly as much an unapproved new drug as a poor one.

This is why the 40-amino-acid classification line and the research-use framing of enforcement activity recur in this area. What a substance is, for regulatory purposes, and what it is offered for, determine the pathway it falls under. Analytical characterisation operates on a different axis entirely.

Red lists, green lists, and the removal petition

An import alert’s red list is not permanent. The corresponding green list identifies products and firms approved for removal from DWPE status, and the route between them is a petition to FDA’s Division of Import Operations. There is no form. The agency’s published position is that removal requires evidence that the conditions leading to DWPE have been resolved and that future shipments will be safe and compliant, with the nature of that evidence varying according to the nature of the violation.

The supporting documentation FDA describes as potentially relevant is a familiar list: root cause analysis, description of corrective actions, description of preventive measures, proof of registration or listing, third-party laboratory analyses, third-party audits, copies of product labelling, certificates of analysis. Third-party analyses and certificates of analysis appear here in their proper role — documentary evidence submitted by a firm to support a specific administrative request, evaluated by a specific office. That is the setting in which analytical documents carry regulatory weight.

The asymmetry is worth naming. The evidence that moves a firm from red list to green list is largely evidence about its systems, labelling, and promotion, assembled to answer a question about admissibility. It is not a lot-level quality determination, and a green-list entry is not a certification that subsequent material meets any specification. The listing describes the agency’s examination posture toward future entries, and nothing more.

What happens to a refused shipment

Under section 801(a), an article refused admission is destroyed unless it is exported within ninety days of the notice of refusal, or within such additional time as the applicable regulations permit. Reconditioning — bringing an article into compliance so it may be admitted, under section 801(b) — is not available in every case: where the refusal rests on the appearance of a violation under 801(a)(1), reconditioning under 801(b) is precluded.

Separately, FDA holds administrative destruction authority over certain refused drugs. Section 708 of the Food and Drug Administration Safety and Innovation Act, enacted in 2012, permits destruction without an opportunity for export of a refused drug valued at $2,500 or less — or such higher amount as the Secretary of the Treasury may set by regulation — and directs FDA to issue regulations providing the owner or consignee notice and an opportunity to present testimony beforehand. FDA began implementing the authority on 4 April 2016; the final rule was published on 31 May 2024 and took effect on 1 July 2024. Its stated rationale is that most products falling within the authority arrive through international mail, in parcels that may contain adulterated, misbranded, unapproved, counterfeit, or tainted articles.

Note again what is and is not happening. Destruction under this authority follows a refusal, and the refusal rests on the appearance standard. A parcel is not destroyed because its contents were assayed and failed; it is destroyed because it was refused admission and export was unavailable or not pursued.

What the border record is evidence of

Put the pieces together and the interpretive rule falls out cleanly, with symmetric consequences.

A refusal or a red-list entry is not a laboratory result. It does not establish that a lot was impure, misidentified, or degraded, and it should not be cited as though it were an identity or purity finding. What it establishes is that the agency’s examination posture toward a firm or product has changed, on grounds usually concerning regulatory status, promotion, or inspection history.

Equally, the absence of an entry is not a clearance. A firm not appearing on a red list has not been examined and found satisfactory; it has not been the subject of a standing instruction. Reading a blank record as an endorsement inverts the mechanism just as thoroughly as reading a detention as an assay.

The analytical record remains where it always was: on the certificate of analysis and in the methods behind it. Whether the methods were validated, whether reference standards were qualified, whether elemental and nitrosamine impurity questions were addressed by appropriate techniques — these are documentary questions with documentary answers, and none of them are answered at a port of entry.

Reading the mechanism for what it is

Import alerts do a legitimate job well suited to their design. They let a finite inspection capacity be pointed at entries where historical information suggests elevated risk, and they shift the burden of demonstrating admissibility onto the party best positioned to document it. The published lists, the petition route, and the notice-and-testimony procedures make the system unusually legible for an administrative process.

What the system does not do is measure anything about the material in a given shipment. Its standard is appearance; its default action is detention without examination; its basis, in the alert most relevant here, is regulatory status rather than composition. The same discipline that applies to a “GMP-grade” claim or a Drug Master File reference applies here in reverse: identify the process the record belongs to, ask what that process determines, and keep the evaluable evidence — methods, parameters, results — separate from the administrative one.